The Committee adopted the CHMP recommendation and scientific discussion, together with a list of questions for the applicant. (European Medicines Agency) - Aug 30, 2026 - CHMP Final
Minutes of the meeting on 23 - 26 Feb 2026: CHMP discussed the issues identified in the application for the treatment of myelofibrosis and polycythaemia vera in adults, and graft-versus-host disease in adults and children.
CHMP • Graft versus Host Disease • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|